Proactive Investors - Run By Investors For Investors

Critical year ahead of drug development for Midatech Pharma

Jim Phillips, chief executive at Midatech Pharma Plc (LONMTPH, NASDAQ:MTP), updates Proactive's Andrew Scott on their three high-value, lead programmes progressing through pre-clinical and clinical development.

The key to each of those programmes is Midatech’s technology which allows it to precisely deploy drugs into the body.

Its two platforms – carbohydrate-coated gold nano-particles and its sustained release system – are about getting medicines to the right place in the right quantities at the right time.

Last month they secured a US$15mln, four-year senior loan facility to help bankroll the programmes.

 
Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full MTPH profile View Profile

Midatech Pharma PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use